Five‐year follow‐up of incretin‐based therapy in a patient with KCNJ11 ‐related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction

Read full text Summarise with VIRAT
Authors: Toshiaki Ohkuma, Ryoichiro Aotani, Wakako Sakamoto, Ayaka Oshiro, Tetsuro Ago
Cited by: 0
References: 6

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Permanent neonatal diabetes mellitus (PNDM) is commonly caused by pathogenic variants in KCNJ11 that impair insulin secretion through ATP‐sensitive potassium (K ATP ) channel dysfunction. Sulfonylureas (SUs) can stimulate insulin secretion and enable insulin discontinuation, but insulin withdrawal may remain difficult even under high‐dose SU, especially when therapy is initiated later in life. We describe a woman with KCNJ11 ‐related PNDM who achieved insulin discontinuation after adding sitagliptin, followed by further improvement with semaglutide during a five‐year follow‐up. HbA 1c remained between 6.1% and 6.5% on semaglutide 0.25 mg/week, with a 60% reduction in glibenclamide and preserved endogenous insulin secretion. A transient HbA 1c rise after semaglutide interruption, followed by improvement upon resumption, confirmed its reversible effect. No episodes of severe hypoglycemia or gastrointestinal adverse events occurred. This case suggests that combining insulin secretagogues targeting both K ATP ‐dependent (triggering: SU) and K ATP ‐independent (amplifying: incretin‐based therapy) pathways may provide additive or synergistic benefits in PNDM.

Fields of Study & Subjects

Pancreatic function and diabetes Diabetes Treatment and Management Diabetes and associated disorders

Publication details

Journal / source
Journal of Diabetes Investigation
Volume
17
Issue
6
Pages
1075–1078
Publication date
31 March 2026
Language
EN